Loading…
ADIL
Adial Pharmaceuticals Inc
NASDAQ· Healthcare· Biotechnology· CUSIP 00688A304
$5.60-1.58%Price as of Aug 29, 18:43 UTC · updated once a day, after the close
Key metrics
- Market cap
- $16.43M
- P/E
- —
- Forward P/E
- —
- P/B
- —
- Dividend yield
- —
- Payout
- —
- EPS
- -$17.71
- ROE
- -2011.64%
- Profit margin
- 0.00%
- Revenue growth
- —
- Beta
- 1.29
- 52-week high
- $10.75
- 52-week low
- $1.31
History
How the company evolved, year by year. Revenue and debt come from the annual reports — for most companies, the 10-K filings with the SEC since 2009; dividends from the payments themselves.
The bars are a balance on the closing date; the lines are what happened during the year. Revenue above equity is ordinary, not an anomaly — it means the company turns its capital over more than once a year.
Investors holding this
Major managers that reported this stock in their latest 13F.
Price over time
▼ -99.8% over 5Y.
today you would have $1.57▼ -99.8%
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
Indicators, year by year
The last 4 closed years. Each multiple uses that year’s closing price and that year’s reported numbers — not today’s. The range is set by the annual reports on record.
| Indicator | Median | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Year-end price | $5.50 | $25.25 | $46.50 | $137.50 | |
| P/B | 1.4x | 1.2x | 1.6x | 0.8x | 1.8x |
| EPS | -$11.93 | -$68.01 | -$90.00 | -$317.75 | |
| ROE | -237.80% | -151.18% | -324.41% | -125.46% | -388.57% |
Median, not average: a single year of near-zero profit produces a P/E of 400 and would drag an average on its own. P/E years above 200x are left out, the same cut the fair price uses — so this median matches the “its own history” method below. Price and EPS have no median: they are series that grow.
Others in the same sector
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| PLURPluri Inc. | $1.53 | — | — | — | — | $16.51M |
| CTXRCitius Pharmaceuticals, Inc. | $0.60 | — | 0.2x | — | -81.09% | $16.53M |
| MDCXMedicus Pharma Ltd. | $0.26 | — | — | — | -7446.11% | $16.28M |
| SCNXScienture Holdings, Inc. | $0.39 |
About the company
Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. The company's lead product is AD04, a serotonin-3 antagonist, which is in Phase 3 clinical trials for the treatment of alcohol use disorder. It is also involved in the development of drug candidates for non-opioid pain reduction and other diseases and disorders. The company was founded in 2010 and is based in Glen Allen, Virginia.
- 5
- Glen Allen, United States
Company description provided by Yahoo Finance.